arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

ACTUATE THERAPEUTICS, INC.

ACTU

$1.10 ▼ -0.12 (-10.16%) at close

14 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

ACTUATE THERAPEUTICS, INC. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap $25.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -119.1% ↘

FCF / Share $-0.21

Trailing P/E —

Price / Book 6.9x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-5.63M

↑ +10.9% —

FCF / Share Free cash flow per share

$-0.21

↑ +10.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Financial Health ↑

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	25.0% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	N/M	54.5% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	92.9% Excellent → Excellent Stable Year-over-year change in earnings per share Optimal: > 10%	94.1% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	N/M	87.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-8.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	10.9% Fair ↓ Fair Declining Year-over-year change in net income	29.4% Excellent ↑ Excellent Improving Year-over-year change in net income	23.9% Good ↑ Good Improving Year-over-year change in net income	23.9% Good ↑ Good Improving Year-over-year change in net income	23.9% Good ↑ Good Improving Year-over-year change in net income	15.3% Good ↑ Good Improving Year-over-year change in net income	-57.4% Weak Weak Year-over-year change in net income	-57.4% Weak Weak Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	10.0% Fair Fair Year-over-year change in free cash flow	—	—	—	93.1% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	0.89x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.06x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.73x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	0.63x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-119.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-46.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	177.7% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	98.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-4973.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-79.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	3.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	5.7% Caution → Caution Stable Return earned on debt + equity capital invested Optimal: > 10%	6.0% Caution ↑ Caution Improving Return earned on debt + equity capital invested Optimal: > 10%	5.6% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	5.1% Caution Caution Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-64.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-33.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-85.7% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-142.0% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-70.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-37.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-314.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	-254.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-148.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1091%)	-57.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-483%)	-57.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-485%)	238.0% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+1487%)	124.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+728%)	—	-154.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1132%)	7.3% Caution → Caution Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-52%)	7.7% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-49%)	7.6% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-49%)	5.7% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-62%)	6.1% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-59%)	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Interest Coverage (x)	—	—	-77.12x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—	—	—	—	—	—	—	—
Net Debt (USD)	$-8.13M	$-13.16M	$-16.92M	$-6.49M	$-3.89M	—	$-13.52M	$-351.71K	—	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-0.24	$-0.18	$-0.25	$-0.30	$-0.32	$1.22	$-0.55	$-4.20	$-5.40	$-5.11	$-4.31	$-3.88	—	—
Free Cash Flow per Share (USD)	$-0.21	—	$-0.31	$-0.21	$-0.24	—	—	—	$-3.42	—	$-3.83	—	—	—
Book Value per Share (USD)	$0.16	$0.34	$0.47	$-0.13	$-0.26	$0.01	$0.27	$-67.58	$-70.20	$-58.92	$-62.58	$-60.44	—	—
Tangible Book Value per Share (USD)	$0.16	$0.34	$0.47	$-0.13	$-0.26	$0.01	$0.27	$-67.58	$-70.20	$-58.92	$-62.58	$-60.44	—	—
Basic Weighted Avg Shares (shares)	23.54M	—	21.39M	19.65M	19.50M	—	10.77M	1.57M	1.54M	—	1.47M	1.42M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$3.80M	$7.94M	$11.07M	$-2.51M	$-4.91M	$405.40K	$5.77M	$-19.52M	—	$-3.93M	—	—	—	—
Total Equity (USD)	$3.78M	$7.92M	$10.94M	$-2.65M	$-5.09M	$104.19K	$5.36M	$-114.26M	$-107.77M	$-99.63M	$-92.14M	$-85.95M	$-80.50M	$-75.31M

📋 What is driving earnings? 2 metrics

Metric	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Income, GAAP (USD)	$-5.63M	$-4.55M	$-6.32M	$-6.32M	$-6.32M	$-6.45M	$-8.30M	$-8.30M	$-8.30M	$-7.61M	$-5.27M	$-5.27M	—	—
Operating Cash Flow (USD)	$-5.02M	$-3.74M	$-6.68M	$-4.17M	$-4.62M	$-4.77M	—	—	$-5.25M	$-5.51M	$-5.64M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters

ACTUATE THERAPEUTICS, INC.

Analytical Summary

14-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ACTU with peers